Jeffrey Schratz, MD
Surgery · Lockport, NYNPI 1649222134
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (41.2%), other and food and beverage — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 82.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $888 and has fallen 94.2% since, to $52 in 2025.
Across 50 payments — averaging $101.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Medtronic$140
- Organogenesis Inc.$127
- Integra Lifesciences Corporation$84
- Smith+Nephew$75
- Johnson & Johnson$65
- plus $406 from 13 others
What the payments were for
- Food & beverage$89718%
- Education$2,10041%
- Other$2,10041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 6 | $4,200 |
| Medtronic(2 entities) | 8 | $140 |
| Organogenesis Inc. | 8 | $127 |
| Integra Lifesciences Corporation | 2 | $84 |
| Smith+Nephew | 5 | $75 |
| Johnson & Johnson | 4 | $65 |
| Fujifilm Healthcare Americas Corporation | 3 | $60 |
| Braintree Laboratories, Inc. | 1 | $51 |
| Davol Inc. | 2 | $47 |
| Boston Scientific | 2 | $45 |
| Venclose Inc. | 1 | $35 |
| Solventum Corporation | 1 | $28 |
| Redhill Biopharma Inc. | 1 | $24 |
| Lifenet Health | 1 | $23 |
| Abbott | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Sanara Medtech Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Biotronik Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Celerity$4,200
How this compares
$5,097 in reported general payments places this provider in the 70th percentile of 1,596 surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 11 | $7,268 |
| Mesalamine DrMesalamine | 21 | $5,857 |
| Sucralfate | 62 | $2,138 |
| Misoprostol | 12 | $778 |
| Dicyclomine Hcl | 32 | $681 |
| Famotidine | 95 | $445 |
| Omeprazole | 53 | $416 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $196 |
| Metronidazole | 11 | $77 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $45 |
Paid to pharmacies, not to this prescriber.
Other surgery in Lockport
- Cheguevara AfanehNew York$1.4M
- Flavio Malcher Martins de OliveiraNew York$695K
- Yuri NovitskyNew York$548K
- Rasa ZarnegarNew York$478K
- Tanuja DamaniNew York$459K
- Benjamin SadowitzSyracuse$419K
- Stephen GoldstoneNy$386K
- Rache SimmonsNew York$371K
- George DenotoManhasset$333K
- Marina KurianNew York$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.